[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653334":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":28,"studyPopulation":21,"armGroups":29,"interventions":37,"overallOfficials":21,"centralContacts":47,"locations":53,"responsibleParty":69,"collaborators":21,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":21,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":94,"whyStopped":21,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Huons Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":21},[9,13],{"measure":10,"description":11,"timeFrame":12},"AUCτ","Area Under the Curve of telmisartan, atorvastatin","Day 22",{"measure":14,"description":15,"timeFrame":12},"Cmax,ss","Maximum concentration at steady state of telmisartan, atorvastatin",[17,19],{"measure":14,"description":18,"timeFrame":12},"Maximum concentration at steady state of 2-hydroxy atorvastatin",{"measure":10,"description":20,"timeFrame":12},"Area Under the Curve of 2-hydroxy atorvastatin",null,{"allocation":23,"interventionModel":24,"interventionModelDescription":21,"primaryPurpose":25,"observationalModel":21,"timePerspective":21,"maskingInfo":26},"NA","SINGLE_GROUP","BASIC_SCIENCE",{"masking":27,"maskingDescription":21,"whoMasked":21},"NONE","For selected subjects, the designated investigational products are administered orally with 200 mL of water during Treatment 1 (HUC2-744-A), Treatment 2 (HUC2-744-B), and Treatment 3 (HUC2-744-A + HUC2-744-B).",[30],{"label":31,"type":32,"description":33,"interventionNames":34},"single arm","EXPERIMENTAL","IP are administered during Treatment 1 (Atorvastatin), Treatment 2 (Telmisartan), and Treatment 3 (Atorvastatin + Telmisartan)",[35,36],"Drug: Atorvastatin Calcium","Drug: Telmisartan",[38,43],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":21},"DRUG","Atorvastatin Calcium","HUC2-744-A",[31],{"type":39,"name":44,"description":45,"armGroupLabels":46,"otherNames":21},"Telmisartan","HUC2-744-B",[31],[48],{"name":49,"role":50,"phone":51,"phoneExt":21,"email":52},"Huons","CONTACT","+82-70-7492-6023","jywon@huons.com",[54],{"facility":55,"status":21,"city":56,"state":57,"zip":58,"country":59,"countryCode":21,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Korea University Anam Hospital","Seoul","Seongbuk-gu","02841","South Korea",{"type":61,"coordinates":62},"Point",[63,64],126.9784,37.566,{"lat":64,"lon":63},[67],{"name":55,"role":50,"phone":68,"phoneExt":21,"email":52},"+82-02-1577-0083",{"type":70,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100653334","phase-1-a-clinical-trial-to-evaluate-the-drug-drug-interactions-of-co-administered-huc2-744-a-and-huc2-744-b-in-healthy-adult-volunteers-100653334",false,"NCT07784608","A Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers","An Open-label, Fixed-sequence, 3-period Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers","DDI","Inclusion Criteria:\n\n* Healthy adults\n* Subjects with a body weight of 50 kg or more and a BMI within the range of 18.0 to 29.9 kg\u002Fm²\n\nExclusion Criteria:\n\n* History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease\n* Presence of acute disease symptoms within 28 days prior to the first dosing\n* History of any disease that may affect drug absorption, distribution, metabolism, or excretion\n* Hypersensitivity or history of clinically significant hypersensitivity to atorvastatin, telmisartan, drugs containing ingredients of the same class, or other medications (e.g., aspirin, antibiotics, dihydropyridine derivatives)",true,"ALL","19 Years","55 Years",{"count":84,"type":85},28,"ESTIMATED","INTERVENTIONAL",[88],"PHASE1","This study aims to evaluate the pharmacokinetic interactions between HUC2-744-A and HUC2-744-B following monotherapy or co-administration under multiple-dose conditions.",[91],"Drug-drug Interactions",[93],"Drug-Drug Interactions","NOT_YET_RECRUITING","2026-09-06",{"date":97,"type":98},"2026-09-10","ACTUAL",{"date":100,"type":85},"2026-09",{"date":102,"type":85},"2027-11",{"name":5,"class":6},1]